Apyx Medical upgraded to Outperform from Market Perform at Citizens JMP

Citizens JMP upgraded Apyx Medical (APYX) to Outperform from Market Perform with an $8 price target following the Q3 report. The shares “are “inflecting” due to its latest offering, the AYON system, the analyst tells investors in a research note. The firm believes AYON, an all-in-one, single console product integrating Apyx’s legacy Renuvion technology with five other surgical offerings, is positioned to benefit from its “differentiated” technological offerings, ability to streamline operating workflow, and a large and growing patient base. Citizens cites AYON’s prospective appeal to physicians for the upgrade.